Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: Long-term follow-up study of 394 patients

American Journal of Gastroenterology

Volumn 101, Issue 12, 2006, Pages 2769-2776

  Gisbert, Javier P ^a,e   Niño, Pilar ^b   Rodrigo, Luis ^b   Cara, Carlos ^c   Guijarro, Luis G ^d  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c CelltechUCB Pharma

^d UNIVERSITY OF ALCALÁ   (Spain)

^e NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MESALAZINE; THIOPURINE METHYLTRANSFERASE;

ADULT; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOCHEMISTRY; ULCERATIVE COLITIS;

ADULT; AZATHIOPRINE; BONE MARROW DISEASES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 33845415085     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00843.x     Document Type: Article

References (57)

1. Gisbert JP, Gomollon F, Mate J, et al. Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterol Hepatol 2002;25:401-15.
2. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000:CD000545.
3. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000:CD000067.
4. Gisbert JP, Gomollon F, Mate J, et al. Individualized therapy with azathioprine or 6-mercaptopurine by monitoring thiopurine methyl-transferase (TPMT) activity. Rev Clin Esp 2002;202:555-62.
5. Aberra FN, Lichtenstein GR. Review article: Monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther 2005;21:307-19.
6. Al Hadithy AF, de Boer NK, Derijks LJ, et al. Thiopurines in inflammatory bowel disease: Pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005;37:282-97.
7. Coulthard S, Hogarth L. The thiopurines: An update. Invest New Drugs 2005;23:523-32.
8. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005;20:1149-57.
9. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6; discussion 16-9.
10. Menor C, Fueyo JA, Escribano O, et al. Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: Comparison with the radiochemical method. Ther Drug Monit 2001;23:536-41.
11. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995;131:193-7.
12. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001;19:2293-301.
13. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
14. Lowenthal A, Meyerstein N, Ben-Zvi Z. Thiopurine methyltransferase activity in the Jewish population of Israel. Eur J Clin Pharmacol 2001;57:43-6.
15. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998;125:879-87.
16. Park-Hah JO, Klemetsdal B, Lysaa R, et al. Thiopurine methyltransferase activity in a Korean population sample of children. Clin Pharmacol Ther 1996;60:68-74.
17. Kroplin T, Weyer N, Gutsche S, et al. Thiopurine S-methyltransferase activity in human erythrocytes: A new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 1998;54:265-71.
18. Szumlanski CL, Honchel R, Scott MC, et al. Human liver thiopurine methyltransferase pharmacogenetics: Biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992;2:148-59.
19. Gisbert JP, Luna M, Mate J, et al. Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Med Clin (Barc) 2003;121:1-5.
20. Gisbert JP, Gomollon F, Cara C, et al. Thiopurine methyltransferase activity in inflammatory bowel disease. A study on 7046 Spanish patients. Med Clin (Barc) 2005;125:281-5.
21. Gisbert JP, Luna M, Maté J, et al. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 2006;53:399-404.
22. Gisbert JP, Gomollón F, Cara C, et al. Thiopurine methyltransferase (TPMT) activity in Spain: A study on 14545 patients. Dig Dis Sci 2006: [in press].
23. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456-9.
24. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464-75.
25. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001;49:656-64.
26. Lowry PW, Szumlanski CL, Weinshilboum RM, et al. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 1999;116:1505-6.
27. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49:665-70.
28. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001;40:723-51.
29. Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 2005;22:605-11.
30. Dewit O, Vanheuverzwyn R, Desager JP, et al. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:79-85.
31. Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006;12:251-7.
32. Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 2001;13:1297-301.
33. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity. Gut 1996;39:401-6.
34. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 2002;16:389-98.
35. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15.
36. Menor C, Fueyo J, Escribano O, et al. Thiopurine methyltransferase activity in a Spanish population sample: Decrease of enzymatic activity in multiple sclerosis patients. Mult Scler 2002;8:243-8.
37. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
38. Reuther LO, Sonne J, Larsen NE, et al. Pharmacological monitoring of azathioprine therapy. Scand J Gastroenterol 2003;38:972-7.
39. Hindorf U, Lyrenas E, Nilsson A, et al. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1105-12.
40. Wright S, Sanders DS, Lobo AJ, et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004;53:1123-8.
41. Mardini HE, Arnold GL. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. J Clin Gastroenterol 2003;36:390-5.
42. Anstey A, Lennard L, Mayou SC, et al. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: A review. J R Soc Med 1992;85:752-6.
43. Lorenzen I, Brun C, Videbaek A. Treatment of immunologic diseases with cytostatics. Acta Med Scand 1969;185:501-6.
44. Ginzler E, Sharon E, Diamond H, et al. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum 1975;18:27-34.
45. Mertens HG, Hertel G, Reuther P, et al. Effect of immunosuppressive drugs (azathioprine). Ann N Y Acad Sci 1981;377:691-9.
46. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:641-9.
47. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5.
48. Naughton MA, Battaglia E, O'Brien S, et al. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford) 1999;38:640-4.
49. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:395-400.
50. Sayani FA, Prosser C, Bailey RJ, et al. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: Effect on cost and adverse events. Can J Gastroenterol 2005;19:147-51.
51. Kader HA, Wenner WJ Jr, Telega GW, et al. Normal thiopurine methyltransferase levels do not eliminate 6- mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 2000;30:409-13.
52. Zelinkova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006;4:44-9.
53. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:1743-50.
54. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001;48:591-2.
55. Ho GT, Lees C, Satsangi J. Pharmacogenetics and inflammatory bowel disease: Progress and prospects. Inflamm Bowel Dis 2004;10:148-58.
56. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003;3(suppl 1):S30-8.
57. Dubinsky MC. Optimizing immunomodulator therapy for inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:506-11.